IP Group (IPO) H1 2025 earnings summary

Executive summary

• Delivered GBP 30.3 million in cash proceeds in H1 2025, a 791% increase year-over-year, driven by successful exits and IPOs, notably Hinge Health and gains in Oxford Nanopore.

• NAV per share stabilized at 96.2p at 30 June 2025, with a post-period increase to about GBP 1, reflecting resilience despite market and FX headwinds.

• Strong liquidity with gross cash and deposits of GBP 237.3 million, up 47% year-over-year, supporting ongoing investments and an accelerated share buyback programme.

• Continued disciplined capital allocation, investing GBP 35.7 million across 22 companies, with a focus on existing portfolio and select new opportunities.

• Significant value potential identified in UK science and technology, positioning for attractive shareholder opportunities.

Financial highlights

• Gross cash at GBP 237.3 million, up from GBP 161.3 million in HY24; NAV at GBP 883.1 million, down from GBP 952.5 million at FY24.

• Loss for the period was GBP 43.0 million, mainly due to provisions on two assets and FX losses, a significant improvement from GBP 109.9 million loss in HY24.

• Net overheads reduced by 12-15% year-over-year, with a target of 23% reduction by year-end.

• Share buybacks retired 6% of share capital in H1, 15% to date, with GBP 75 million program ongoing.

• Portfolio value at GBP 799.9 million, with over 55% concentrated in top 10 holdings.

Outlook and guidance

• Confident in achieving over GBP 250 million of exits by end-2027, with strong momentum into H2.

• Positive market sentiment and strong pipeline of milestones expected through 2027.

• FY25 priorities include achieving positive NAV per share, delivering cash exits exceeding GBP 250 million, returning 50% of cash exits, and growing the opportunity pipeline.

• Portfolio well-funded: one-third funded to profitability, one-third needs funding in 12-18 months, one-third post-2027.

• Well positioned to benefit from UK pension reforms and increased institutional capital.